Evidence map›Paper›PMID 29061512›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2017

Injectable hydrogels for ophthalmic applications.

Kai Wang, Zongchao Han

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. [Retinal protective effects of zincZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Long-Acting Ocular Injectables: Are We Looking In The Right Direction?Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kai WangDepartment of Ophthalmology, University of North Carolina, Chapel Hill, NC 27599, USA.
Zongchao HanDepartment of Ophthalmology, University of North Carolina, Chapel Hill, NC 27599, USA; Carolina Institute for Nano Medicine, University of North Carolina, Chapel Hill, NC 27599, USA; Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: zongchao@med.unc.edu.

Funding

Targeting Retinitis Pigmentosa Using Nanoparticle-Mediated Delivery of Genomic DNAR01EY026564 · NEI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAN, ZONGCHAO · 2016 to 2020
$1.9M
Nanoparticle-mediated gene delivery for rhodopsin-associated retinitis pigmentosaR21EY024059 · NEI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAN, ZONGCHAO · 2014 to 2015
$408k
NEI NIH HHS R01 EY026564NEI NIH HHS R21 EY024059
6 · The paper itself

Abstract

The demand for effective eye therapies is driving the development of injectable hydrogels as new medical devices for controlled delivery and filling purposes. This article introduces the properties of injectable hydrogels and summarizes their versatile application in the treatment of ophthalmic diseases, including age-related macular degeneration, cataracts, diabetic retinopathy, glaucoma, and intraocular cancers. A number of injectable hydrogels are approved by FDA as surgery sealants, tissue adhesives, and are now being investigated as a vitreous humor substitute. Research on hydrogels for drug, factor, nanoparticle, and stem cell delivery is still under pre-clinical investigation or in clinical trials. Although substantial progress has been achieved using injectable hydrogels, some challenging issues must still be overcome before they can be effectively used in medical practice.

Indexed as

Drug Delivery SystemsAnimalsEye DiseasesHumansHydrogelsInjectionsHydrogelsDrug delivery systemInjectable hydrogelsOphthalmologyRegenerative medicine

Identifiers

PMID29061512
PMCPMC5722685

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.